Clinical trials: Adult Soft Tissue Sarcoma
Adult Solid Neoplasm, Bladder Carcinoma
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
This phase I trial studies the side effects of vaccine therapy and pembrolizumab in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment, that…
- Conditions
- Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative
- Trial name
- NCT02432963
- Testing
- Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
Cancer, Pediatric Cancer
Digital Art Therapy for Young Cancer Survivors
This is a single-site, single-arm, interventional study assessing the feasibility of the ARTCan Therapy Application (App) and whether it is an acceptable means of administering art therapy to young adult cancer survivors.
- Conditions
- Cancer, Pediatric Cancer, Pediatric Malignancies, Pediatric Sarcoma of Soft Tissue
- Trial name
- NCT06789666
- Testing
- ARTCan App
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Soft Tissue Sarcoma Adult
Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcomas
"Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcoma" is a prospective study with additional translational research using preoperative and postoperative tissue, blood…
- Trial name
- NCT06385288
- Testing
- Blood and tissue collection for immunological studies, advanced imaging., neoadjuvant Therapy
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University Hospital Tuebingen
Soft Tissue Sarcoma, Sarcoma,Soft Tissue
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
This study is being done to find out whether the study drug Retifanlimab, a monoclonal antibody against the PD-1 protein, combined with gemcitabine and docetaxel, is a safe and effective treatment for your disease.
- Conditions
- Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Soft Tissue Sarcoma Adult
- Trial name
- NCT04577014
- Testing
- Retifanlimab, Gemcitabine, Docetaxel
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Small Cell Lung Cancer Extensive Stage, Brain Metastases
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
To characterize feasibility, safety, and/or preliminary efficacy of personalized strategies to adapt standard radiotherapy treatments to individual patient responses.
- Conditions
- Small Cell Lung Cancer Extensive Stage, Brain Metastases, Solid Tumor, Adult, Thoracic Cancer
- Trial name
- PRISM (NCT07139990)
- Testing
- Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort C: Sarcoma Pre-Operative PULSAR
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Texas Southwestern Medical Center
Soft Tissue Sarcoma Adult, Soft Tissue Sarcoma (Excluding GIST)
Assessment of the Long-term Efficacy of Moderately Hypofractionated Neoadjuvant Radiotherapy Soft Tissue Sarcoma in the Limbs or Trunk Wall
This trial aims to assess the long-term efficacy of moderately hypofractionated neoadjuvant radiotherapy for soft tissue sarcoma in the limbs or trunk wall.
- Conditions
- Soft Tissue Sarcoma Adult, Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma of the Trunk and Extremities, Soft Tissue Sarcoma of the Limb
- Trial name
- NEORASARC (NCT07507773)
- Testing
- Moderately hypofractionated neoadjuvant radiotherapy
- Where
- France
- Volunteers
- 135 people
- Sponsor
- Centre Oscar Lambret
Solid Tumor, Adult, Cancer
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable.
- Conditions
- Solid Tumor, Adult, Cancer, Neoplasms, Sarcoma
- Trial name
- BETA-PRIME (NCT04673942)
- Testing
- AdAPT-001, Checkpoint Inhibitor, Immune
- Where
- 6 sites in United States
- Volunteers
- 140 people
- Sponsor
- EpicentRx, Inc.
Advanced Malignant Neoplasm, Castleman Disease
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body…
- Conditions
- Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease
- Trial name
- NCT01552434
- Testing
- Bevacizumab, Cetuximab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- M.D. Anderson Cancer Center
Soft Tissue Sarcoma Adult, Advanced Cancer
Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study
This is a multicenter study assessing the efficacy of nivolumab in association with relatlimab.
- Trial name
- CONGRATS (NCT04095208)
- Testing
- Association of Nivolumab + Relatlimab, Nivolumab
- Where
- 5 sites in France
- Volunteers
- 68 people
- Sponsor
- Institut Bergonié
Recurrent Adult Soft Tissue Sarcoma
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
This phase II trial studies the side effects of hypofractionated radiation therapy in treating patients with soft tissue sarcomas prior to surgery.
- Trial name
- NCT02701153
- Testing
- Conventional Surgery, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Soft Tissue Sarcoma Adult, Undifferentiated Pleomorphic Sarcoma
Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients
This is a biology driven, monocentric study, designed to identify biomarkers of activity of trabectedin in patients with advanced non-L soft-tissue sarcoma.
- Conditions
- Soft Tissue Sarcoma Adult, Undifferentiated Pleomorphic Sarcoma, Epithelioid Sarcoma, Solitary Fibrous Tumors
- Trial name
- PIPER (NCT04008238)
- Testing
- Trabectedin
- Where
- France
- Volunteers
- 29 people
- Sponsor
- Institut Bergonié
Advanced Solid Tumor, Advanced Colorectal Carcinoma
Combining Epigenetic And Immune Therapy to Beat Cancer.
Umbrella study structure to independently and simultaneously assess the effects of the association of durvalumab and tazemetostat in multiple solid tumors.
- Conditions
- Advanced Solid Tumor, Advanced Colorectal Carcinoma, Advanced Soft-tissue Sarcoma, Advanced Pancreatic Adenocarcinoma
- Trial name
- CAIRE (NCT04705818)
- Testing
- Durvalumab, Tazemetostat
- Where
- 3 sites in France
- Volunteers
- 164 people
- Sponsor
- Institut Bergonié
Sarcoma, Sarcoma, Leiomyo-, Adult
Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients
This is a cohort study aimed at developing a stratified medicine approach for personalised neoadjuvant chemotherapy (NCT) in high-risk soft tissue sarcoma (STS) patients with dedifferentiated liposarcoma (DDLPS), leiomyosarcoma…
- Conditions
- Sarcoma, Sarcoma, Leiomyo-, Adult, Sarcoma, Synovial, Adult, Soft Tissue Sarcoma (STS)
- Trial name
- PANTHR-S (NCT07432932)
- Testing
- Observational Translational Study
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Advanced Solid Tumor, Soft Tissue Sarcoma Adult
Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors
This is a Phase 1, first-in-human, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 administered to patients with advanced solid tumors.
- Trial name
- NCT05352750
- Testing
- SON-1010
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Sonnet BioTherapeutics
Soft Tissue Sarcoma Adult
Impact of Locoregional Treatment of Soft Tissue Sarcoma on Status of Patients Aged 70 Years and Over
In order to describe functional impact of surgery in elderly patients treated for lower-limb soft-tissue sarcoma, the investigators set up this project which aims to identify prognostic factors among geriatric and functional…
- Trial name
- SARCOLD (NCT03077178)
- Testing
- Geriatric assessment
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Institut Bergonié
Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma Adult
Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma
The purpose of the study is to investigate whether a personalized selection of patients with localized soft tissue sarcoma for preoperative proton radiation therapy can reduce long-term radiation side effects without increasing…
- Conditions
- Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma Adult, Soft Tissue Sarcoma of the Trunk and Extremities, Synovial Sarcomas
- Trial name
- PROSARC-1 (NCT07169344)
- Testing
- preoperative, Quality of life, Functional outcome
- Where
- 4 sites in Norway
- Volunteers
- 110 people
- Sponsor
- Oslo University Hospital
Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult
Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.
The purpose of the study is to study if dose escalated proton radiotherapy can improve local controll for patients with inoperable soft tissue sarcomas. The standard treatment is photon-based radiation.
- Conditions
- Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult, Soft Tissue Sarcoma of the Trunk and Extremities, Synovial Sarcomas
- Trial name
- PROSARC-2 (NCT07173972)
- Testing
- Definitive radiotherapy
- Where
- 2 sites in Norway
- Volunteers
- 40 people
- Sponsor
- Oslo University Hospital
Soft Tissue Sarcoma Adult
Sarcomas and DDR-Inhibition; a Combined Modality Study
To assess the safety and tolerability profile, in the pre- and perioperative period (up to 30 days post-surgery), of combined modality treatment (CMT) by administering AZD1390 with or without durvalumab and RT concurrently…
- Trial name
- SADDRIN-1 (NCT05116254)
- Testing
- AZD1390 + radiotherapy, AZD1390 + durvlaumab + radiotherapy
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- The Netherlands Cancer Institute
Leiomyosarcoma, Liposarcoma
Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
This study is designed to test the safety and efficacy of the combination of lenvatinib, a drug that can inhibit the growth of supplying vessels around the tumors, and eribulin, a chemotherapy drug that targets the cancer cell…
- Conditions
- Leiomyosarcoma, Liposarcoma, Soft Tissue Sarcoma Adult, Advanced Cancer
- Trial name
- LEADER (NCT03526679)
- Testing
- Eribulin, Lenvatinib
- Where
- 2 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults
Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy
This is a randomized Phase III clinical trial in the setting of localized high-risk soft tissue sarcomas (STS). This study will compare a standard neoadjuvant chemotherapy with epirubicin plus ifosfamide versus a histology-driven…
- Trial name
- NCT01710176
- Testing
- epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3), gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8), trabectedin 1.3 mg/m2
- Where
- 15 sites in Italy, Spain
- Volunteers
- 550 people
- Sponsor
- Italian Sarcoma Group